Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)

Mylène Mabille, Daniel Vanel, Marcela Albiter, Axel Le Cesne, Sylvie Bonvalot, Cécile Le Péchoux, Philippe Terrier, Lorraine G. Shapeero, Clarisse Dromain

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy). Materials and methods: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib. Results: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion. Conclusion: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.

Original languageEnglish
Pages (from-to)204-208
Number of pages5
JournalEuropean Journal of Radiology
Volume69
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Neoplasm Metastasis
Liver
Tomography
Neoplasms
Therapeutics
Recurrence
Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Imatinib Mesylate
Response Evaluation Criteria in Solid Tumors

Keywords

  • GIST
  • Imatinib
  • Sarcomas of the soft tissue: translational oncology-invasion and metastasis
  • Treatment evaluation
  • Tumor imaging: CT and MRI

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). / Mabille, Mylène; Vanel, Daniel; Albiter, Marcela; Le Cesne, Axel; Bonvalot, Sylvie; Le Péchoux, Cécile; Terrier, Philippe; Shapeero, Lorraine G.; Dromain, Clarisse.

In: European Journal of Radiology, Vol. 69, No. 2, 02.2009, p. 204-208.

Research output: Contribution to journalArticle

Mabille, Mylène ; Vanel, Daniel ; Albiter, Marcela ; Le Cesne, Axel ; Bonvalot, Sylvie ; Le Péchoux, Cécile ; Terrier, Philippe ; Shapeero, Lorraine G. ; Dromain, Clarisse. / Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). In: European Journal of Radiology. 2009 ; Vol. 69, No. 2. pp. 204-208.
@article{912d4d4d364345d5bc964f8ac9dc383f,
title = "Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)",
abstract = "Purpose: To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy). Materials and methods: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib. Results: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion. Conclusion: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.",
keywords = "GIST, Imatinib, Sarcomas of the soft tissue: translational oncology-invasion and metastasis, Treatment evaluation, Tumor imaging: CT and MRI",
author = "Myl{\`e}ne Mabille and Daniel Vanel and Marcela Albiter and {Le Cesne}, Axel and Sylvie Bonvalot and {Le P{\'e}choux}, C{\'e}cile and Philippe Terrier and Shapeero, {Lorraine G.} and Clarisse Dromain",
year = "2009",
month = "2",
doi = "10.1016/j.ejrad.2008.10.009",
language = "English",
volume = "69",
pages = "204--208",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)

AU - Mabille, Mylène

AU - Vanel, Daniel

AU - Albiter, Marcela

AU - Le Cesne, Axel

AU - Bonvalot, Sylvie

AU - Le Péchoux, Cécile

AU - Terrier, Philippe

AU - Shapeero, Lorraine G.

AU - Dromain, Clarisse

PY - 2009/2

Y1 - 2009/2

N2 - Purpose: To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy). Materials and methods: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib. Results: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion. Conclusion: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.

AB - Purpose: To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy). Materials and methods: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib. Results: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion. Conclusion: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.

KW - GIST

KW - Imatinib

KW - Sarcomas of the soft tissue: translational oncology-invasion and metastasis

KW - Treatment evaluation

KW - Tumor imaging: CT and MRI

UR - http://www.scopus.com/inward/record.url?scp=59649102913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649102913&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2008.10.009

DO - 10.1016/j.ejrad.2008.10.009

M3 - Article

VL - 69

SP - 204

EP - 208

JO - European Journal of Radiology

JF - European Journal of Radiology

SN - 0720-048X

IS - 2

ER -